肿瘤血液检测市场按生物标记类型、技术、临床应用、癌症类型、最终用户和地区划分

2025 年肿瘤血液学检测市场规模预计为 93.4 亿美元，预计到 2032 年将达到 238.1 亿美元，2025 年至 2032 年的复合年增长率为 14.3%。

全球肿瘤血液学检测市场是更广泛的肿瘤诊断领域中一个具有变革意义的细分市场，从根本上改变了现代医疗保健中癌症检测、监测和治疗决策的方式。

肿瘤血液检测，也称为液态生物检体，是一系列创新的非侵入性诊断技术，用于分析週边血液样本中存在的循环性肿瘤细胞(CTC)、循环肿瘤 DNA (ctDNA)、外泌体和其他肿瘤衍生的生物标记。

这项创新技术相比传统的组织切片检查具有显着优势，包括减轻患者负担、降低手术风险、实现即时监测以及更全面地捕捉肿瘤异质性。其应用领域广泛，涵盖癌症早期筛检与诊断、治疗方案选择、治疗反应监测、微量残存疾病检测等。

随着基因测序技术的进步、人工智慧的融合应用以及越来越多的临床证据支持液态生物检体的有效性，肿瘤血液检测市场正展现出前所未有的成长动能。全球癌症发生率的不断攀升，以及对精准医疗和个人化治疗策略日益增长的需求，正持续推动全球各医疗保健领域的市场扩张。

市场动态

推动全球肿瘤血液学检测市场快速扩张和临床应用的主要因素有很多。其中最主要的成长要素是全球癌症负担的日益恶化。不断上升的发病率要求提供更有效率、更便捷、更人性化的诊断解决方案，以实现早期发现和整个治疗过程中的持续监测。

次世代定序、数位PCR和分子谱分析等技术的进步显着提高了液态生物检体的敏感度和特异性，使其日益被视为侵入性组织取样手术的可行替代方案。随着精准医疗和个人化治疗方案的日益普及，肿瘤血液检测能够以前所未有的精确度即时监测治疗反应、抗药性机制和疾病进展，市场成长也进一步加速。然而，目前仍存在一些显着的局限性，例如先进检测平台的高成本、许多地区医保覆盖范围有限以及新型诊断技术监管方面的复杂性。

此外，不同医疗体系之间缺乏标准化的通讯协定、品管措施和临床指南，为实施带来了挑战，并可能阻碍其广泛应用。儘管有这些局限性，但透过在早期癌症筛检计画中扩大应用、与人工智慧（AI）和机器学习平台整合以提高诊断准确性以及加大研发投入，仍涌现出巨大的机会。加强製药公司、诊断设备製造商和医疗机构之间的合作，为市场扩张提供了巨大的潜力，尤其是在传统切片检查基础设施有限但癌症诊断需求持续快速增长的新兴经济体。

本次调查的主要特点

• 本报告对全球肿瘤血液学检测市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和復合年增长率。
• 它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
• 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 该研究根据以下参数对全球肿瘤血液学检测市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告的研究结果将使负责人和企业经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 这份全球肿瘤血液学检测市场报告的目标受众包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 相关人员可以透过各种策略矩阵轻鬆做出决策，这些矩阵用于分析全球肿瘤血液学检测市场。

目录

第一章 研究目标与前提条件

• 调查目的
• 先决条件
• 简称

第二章 市场范围

• 报告概述
  • 市场定义和范围
• 执行摘要

第三章 市场动态、监管与趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 法规环境
• 产品上市及核准
• PEST分析
• 波特分析
• 併购趋势
• 产业趋势

4. 2020-2032年全球肿瘤血液学检测市场（依生物标记类型划分）

• 循环肿瘤DNA（ctDNA）
• 循环性肿瘤细胞（CTCs）
• 细胞外囊泡（EVs）/外泌体
• 其他无细胞核酸

5. 2020-2032年全球肿瘤血液学检测市场（依技术划分）

• 基于聚合酵素链锁反应(PCR) 的检测
• 次世代定序（NGS）
• 基于微阵列的侦测
• 质谱分析
• 免疫检测

6. 2020-2032年全球肿瘤血液学检测市场（依临床应用划分）

• 早期检测/癌症筛检
• 诊断
• 治疗方案
• 治疗监测
• 微量残存疾病（MRD）检测
• 復发监测/预后

7. 2020-2032年全球肿瘤血液学检测市场（依癌症类型划分）

• 肺癌
• 乳癌
• 大肠直肠癌
• 摄护腺癌
• 膀胱癌
• 恶性黑色素瘤
• 其他癌症（如卵巢癌、胰臟癌、白血病、淋巴瘤）

8. 2020-2032年全球肿瘤血液学检测市场（依最终用户划分）

• 医院
• 专科诊所
• 诊断检查室
• 学术和研究机构
• 製药和生物技术公司

9. 2020-2032年全球肿瘤血液学检测市场（按地区划分）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 澳洲
• 韩国
• ASEAN
• 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第十章 竞争格局

• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Guardant Health
• Bio-Rad Laboratories
• Abbott Laboratories
• Qiagen
• Agilent Technologies
• Thermo Fisher Scientific
• Siemens Healthineers
• GE Healthcare
• BD（Becton, Dickinson and Company）
• PerkinElmer
• Myriad Genetics
• Sysmex Corporation
• Danaher Corporation

第十一章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十二章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Tumor Blood Testing Market is estimated to be valued at USD 9.34 Bn in 2025 and is expected to reach USD 23.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.3% from 2025 to 2032.

The global tumor blood testing market represents a transformative segment within the broader oncology diagnostics landscape, fundamentally reshaping how cancer detection, monitoring, and treatment decisions are approached in modern healthcare.

Tumor blood testing, also known as liquid biopsy, encompasses a revolutionary array of non-invasive diagnostic techniques that analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other tumor-derived biomarkers present in peripheral blood samples.

This innovative approach offers significant advantages over traditional tissue-based biopsies, including reduced patient discomfort, lower procedural risks, real-time monitoring capabilities, and the ability to capture tumor heterogeneity more comprehensively. The market encompasses various applications ranging from early cancer screening and diagnosis to treatment selection, therapeutic monitoring, and minimal residual disease detection.

With advancing genomic sequencing technologies, artificial intelligence integration, and growing clinical evidence supporting liquid biopsy efficacy, the tumor blood testing market is experiencing unprecedented growth momentum. The increasing prevalence of cancer globally, coupled with rising demand for precision medicine approaches and personalized treatment strategies, continues to drive market expansion across diverse healthcare settings worldwide.

Market Dynamics

The global tumor blood testing market is propelled by several compelling drivers that underscore its rapid expansion and clinical adoption. The primary growth driver stems from the increasing global cancer burden, with rising incidence rates necessitating more efficient, accessible, and patient-friendly diagnostic solutions that can facilitate early detection and continuous monitoring throughout treatment journeys.

Technological advancements in next-generation sequencing, digital PCR, and molecular profiling techniques have significantly enhanced the sensitivity and specificity of liquid biopsies, making them increasingly viable alternatives to invasive tissue sampling procedures. The growing emphasis on precision medicine and personalized treatment approaches further accelerates market growth, as tumor blood testing enables real-time monitoring of treatment response, resistance mechanisms, and disease progression with unprecedented accuracy. However, the market faces notable restraints including high costs associated with advanced testing platforms, limited reimbursement coverage in many regions, and regulatory complexities surrounding novel diagnostic technologies.

Additionally, the lack of standardized protocols, quality control measures, and clinical guidelines across different healthcare systems creates implementation challenges that may hinder widespread adoption. Despite these constraints, substantial opportunities emerge through expanding applications in early-stage cancer screening programs, integration with artificial intelligence and machine learning platforms for enhanced diagnostic accuracy, and growing investments in research and development activities. The increasing collaboration between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions presents significant potential for market expansion, particularly in emerging economies where traditional biopsy infrastructure remains limited but demand for cancer diagnostics continues to grow exponentially.

Key Features of the Study

• This report provides in-depth analysis of the global tumor blood testing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tumor blood testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Illumina, Inc., Guardant Health, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Agilent Technologies, Thermo Fisher Scientific, Siemens Healthineers, GE Healthcare, BD (Becton, Dickinson and Company), PerkinElmer, Myriad Genetics, Sysmex Corporation, and Danaher Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global tumor blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor blood testing market

Market Segmentation

• Biomarker Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • Extracellular Vesicles (EVs) / Exosomes
  • Other Cell-Free Nucleic Acids
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Polymerase Chain Reaction (PCR)-Based Testing
  • Next-Generation Sequencing (NGS)
  • Microarray-Based Testing
  • Mass Spectrometry
  • Immunoassays
• Clinical Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Early Detection/Cancer Screening
  • Diagnosis
  • Therapy Selection
  • Treatment Monitoring
  • Minimal Residual Disease (MRD) Detection
  • Recurrence Monitoring/Prognosis
• Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Guardant Health
  • Bio-Rad Laboratories
  • Abbott Laboratories
  • Qiagen
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • GE Healthcare
  • BD (Becton, Dickinson and Company)
  • PerkinElmer
  • Myriad Genetics
  • Sysmex Corporation
  • Danaher Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Tumor Blood Testing Market, By Biomarker Type
  • Global Tumor Blood Testing Market, By Technology
  • Global Tumor Blood Testing Market, By Clinical Application
  • Global Tumor Blood Testing Market, By Cancer Type
  • Global Tumor Blood Testing Market, By End User
  • Global Tumor Blood Testing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Tumor Blood Testing Market, By Biomarker Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Circulating Tumor DNA (ctDNA)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Circulating Tumor Cells (CTCs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Extracellular Vesicles (EVs) / Exosomes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Cell-Free Nucleic Acids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Tumor Blood Testing Market, By Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Polymerase Chain Reaction (PCR)-Based Testing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Next-Generation Sequencing (NGS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Microarray-Based Testing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Mass Spectrometry
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunoassays
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Tumor Blood Testing Market, By Clinical Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Early Detection/Cancer Screening
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Therapy Selection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Treatment Monitoring
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Minimal Residual Disease (MRD) Detection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Recurrence Monitoring/Prognosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Tumor Blood Testing Market, By Cancer Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Tumor Blood Testing Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Academic and Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Tumor Blood Testing Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Biomarker Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Clinical Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Illumina, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Guardant Health
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bio-Rad Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Qiagen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Agilent Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Siemens Healthineers
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GE Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BD (Becton, Dickinson and Company)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PerkinElmer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sysmex Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us